Charles River Laboratories International (NYSE:CRL – Get Free Report) had its target price raised by stock analysts at Royal Bank Of Canada from $322.00 to $352.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada‘s price target suggests a potential upside of 11.43% from the company’s current price.
Several other research firms have also recently commented on CRL. Robert W. Baird increased their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Morgan Stanley boosted their price objective on Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Jefferies Financial Group upped their target price on Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday, September 28th. Zacks Research downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday. Finally, UBS Group assumed coverage on Charles River Laboratories International in a report on Wednesday, September 30th. They set a “buy” rating and a $357.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus target price of $306.50.
Check Out Our Latest Stock Analysis on Charles River Laboratories International
Charles River Laboratories International Price Performance
Shares of NYSE:CRL traded down $10.41 during midday trading on Thursday, reaching $315.88. 901,811 shares of the company’s stock traded hands, compared to its average volume of 962,561. The company has a market cap of $15.08 billion, a P/E ratio of -65.23, a PEG ratio of 3.29 and a beta of 1.36. The company has a fifty day simple moving average of $304.55 and a two-hundred day simple moving average of $224.12. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International has a 1 year low of $146.20 and a 1 year high of $379.63.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. During the same quarter last year, the business posted $2.43 earnings per share. The business’s quarterly revenue was down 2.2% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International will post 11.38 EPS for the current fiscal year.
Insider Buying and Selling at Charles River Laboratories International
In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the sale, the director owned 1,438 shares in the company, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 102,299 shares of company stock worth $31,050,863. 1.30% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Charles River Laboratories International
Several hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after buying an additional 210,260 shares in the last quarter. Bank of America Corp DE raised its stake in Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after acquiring an additional 54,500 shares in the last quarter. Amundi lifted its position in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Van Berkom & Associates Inc. lifted its position in Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after acquiring an additional 50,462 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Charles River Laboratories International by 2.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 225,314 shares of the medical research company’s stock valued at $51,099,000 after acquiring an additional 6,401 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.
Charles River Laboratories International News Roundup
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: Barclays raised its price target to $375 from $330 and reiterated an “overweight” rating, citing potential upside from the recent share price. Barclays stock recommendations
- Positive Sentiment: Third-quarter results topped expectations: adjusted EPS was $3.09 versus estimates near $2.97, and revenue of $982.7 million exceeded the $960.4 million consensus. Organic growth and margin expansion contributed to results, and the company raised its 2026 outlook. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
- Negative Sentiment: Revenue declined 2.2% year over year, despite beating analyst estimates. The contraction may temper investor enthusiasm for the earnings beat and outlook increase. Charles River Laboratories Announces Third-Quarter 2026 Results
- Negative Sentiment: Zacks Research cut its rating from “strong-buy” to “hold,” a counterpoint to Barclays’ upgrade that could weigh on sentiment. Zacks Research stock recommendations
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.
Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
